louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02655185: Novel Risk Factors of Atrial Fibrillation in Patients With Chronic Heart Failure
Official title: Study to Evaluate Association of Blood Lipid Levels With Atrial Fibrillation Incidence in Patients With Chronic Heart Failure
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Heart Failure
Keywords: Lipids
Atrial Fibrillation
Heart Failure
Lead sponsor: Yangzhou No.1 People's Hospital
Sponsor class: OTHER
First posted: 2016-01-13
Enrollment: 300
Sex: ALL
Minimum age (years): 40
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: In-hospital patients with a diagnosis of chronic heart failure will be recruited at Yangzhou No.1 people's hospital, China.

Brief summary: The purpose of this study is to determine whether lipid levels are related with incidence of atrial fibrillation in Patients with chronic heart failure.

Detailed description: Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice. Chronic Heart failure (CHF) has become a major clinical and public health problem. Both AF and CHF often co-exist and complicate each other's administration.Several risk factors have been demonstrated to be associated with the risk of AF in Patients with CHF.

Lopez et al. found that higher levels of low-density lipoprotein cholesterol (LDLc) and total cholesterol were associated with a lower incidence of AF independently of other risk factors from the Atherosclerosis Risk in Communities (ARIC) study.

Thus the purpose of this study is to determine whether lipid levels are related with incidence of atrial fibrillation in Patients with chronic heart failure. This study maybe provide a novel opinion on the prevention of AF in patients with CHF.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of chronic heart failure

Exclusion Criteria:

* Use of statins

Primary outcomes:
measure: Number of participants with newly emerging atrial fibrillation as assessed by electrocardiogram
timeFrame: three years
Secondary outcomes:
measure: Cardiovascular mortality
timeFrame: three years
measure: Worsing heart failure assessed by decreased NYHA class and left ventricular ejection fraction
timeFrame: three years
measure: rate of rehospitalization
timeFrame: three years
Other outcomes:
Locations:
Study officials:
affiliation: Yangzhou No.1 People's Hospital
name: Chen - Liu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01340885: Cognitive Decline in Non-demented PD
Official title: Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Parkinson's Disease
Keywords: attention
mild cognitive impairment
dementia
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
Collaborators: name: National Institute of Neurological Disorders and Stroke (NINDS)
First posted: 2011-04-25
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).

Detailed description: Cognitive dysfunction can occur in early stage of Parkinson's disease (PD) and increases as PD progresses. Attention deficits in PD patients with dementia strongly predict the impairment of their daily living activities.

Previous studies have shown that atomoxetine improves PD executive dysfunction and rivastigmine improves attention deficits in PD patients with dementia without worsening the motor symptoms.

The aim of this study is to examine the effect of atomoxetine and rivastigmine on attention and quality of life in PD patients without disabling cognitive impairment.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Parkinson's disease
* Respond to levodopa therapy

Exclusion Criteria:

* Dementia
* Psychiatric disorders including anxiety disorders, dissociative disorders, mood disorders, schizophrenia and related disorders, or ADD/ADHD
* Any clinically unstable disease such as cancer, HIV/AIDS, heart condition, liver disease, kidney or renal failure or others that might require hospitalization
* Evidence for another neurological disease (history of seizures, Alzheimer disease, multiple sclerosis or other movement disorders);
* Currently using any of the study drugs;
* Colorblindness

Primary outcomes:
measure: Attention Network Effects
timeFrame: 6 weeks
Secondary outcomes:
measure: Quality of Life
timeFrame: 6 weeks
measure: Stroop Color Word Test
timeFrame: 6 weeks
measure: Fatigue
timeFrame: 6 weeks
measure: Depression
timeFrame: 6 weeks
measure: Daytime Sleepiness
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
Study officials:
affiliation: Oregon Health and Science University
name: Jau-Shin Lou, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03435185: Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients
Official title: Greater Occipital and Supraorbital Nerve Blockade For The Preventive Treatment of Migraine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Migraine Disorders
Keywords: Pain
Nerve Blocks
Headache
Local Anaesthetics
Migraine
Lead sponsor: Dr. Lutfi Kirdar Kartal Training and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2018-02-15
Enrollment: 103
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators aimed to evaluate the efficacy of greater occipital nerve and supraorbital nerve blockade with local anesthetics for the preventive treatment of migraine without aura.

Detailed description: A mixture of 1 ml 2% lidocaine and 0.9% 1 ml saline was injected bilaterally to GON and SON in the blockade patients. Placebo patients received 2 ml 0.9% saline in the same way. Patients were blinded to kind of injection.

Eligibility criteria: Inclusion Criteria:

* Lack of benefits 1 year from preventive treatment or intolerance to their treatments.
* 18 ≥ years old
* Migraine without aura for more than 1 year, minimum of two or more migraine attacks per month.

Exclusion Criteria:

* Patients with any chronic illness, medication overuse headache, a history of cranial and cervical surgery
* Allergies to local anesthetics
* Hemorrhagic diathesis
* Alcohol or drug abuse

Primary outcomes:
measure: Change of Frequency of Headache
timeFrame: Patients were followed up from baseline to 2 months after first injection.
measure: Change of Severity of Headache
timeFrame: Patients were followed up for 2 months from baseline after first injection.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Tang Y, Kang J, Zhang Y, Zhang X. Influence of greater occipital nerve block on pain severity in migraine patients: A systematic review and meta-analysis. Am J Emerg Med. 2017 Nov;35(11):1750-1754. doi: 10.1016/j.ajem.2017.08.027. Epub 2017 Aug 14.
Clinical trial NCT01593085: Evaluation of States in Major Depressive Patients With Cancer, Hospitalized in a Hospital Palliative
Official title: Evaluation of States in Major Depressive Patients With Cancer, Hospitalized in a Hospital Palliative
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer
Keywords: palliative cares
cancer
suicide risk
Lead sponsor: Centre Francois Baclesse
Sponsor class: OTHER
First posted: 2012-05-07
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with cancer in palliative cares

Brief summary: The investigators propose a study that aims to develop a methodology for assessing this risk and the psychological consequences of the malignancy in the palliative phase.


Eligibility criteria: Inclusion Criteria:

* Patient (s) age (s) 18 or more
* Patient (s) reach (s) of a cancer palliative stage
* Patient (s) hospital (s) in the palliative care service
* Patient (s) with cognitive function to an interrogation
* Patient (s) having a physical condition for an interview lasting 45 minutes
* Patient (s) that received clear information on the diagnosis and prognosis of their disease.
* Free and informed consent signed

Exclusion Criteria:

* Patient (s) age (s) under 18 years
* Patient (s) under supervision or unable to give informed consent
* Patient (s) whose cognitive functions do not allow an examination.

Primary outcomes:
measure: assessing the prevalence of suicide risk in patients with cancer admitted to a palliative care service.
timeFrame: at inclusion only, during hospitalization in palliative cares
Secondary outcomes:
measure: Evaluate the feasibility of a methodology for estimating the risk of suicide in patients with cancer admitted to a palliative care service
timeFrame: at inclusion only, during hospitalization in palliative cares
measure: Assess the psychological impact of cancer pathology in patients in palliative
timeFrame: at inclusion only, during hospitalization in palliative cares
measure: Identify risk factors for suicide in this patient population
timeFrame: at inclusion only, during hospitalization in palliative cares
Other outcomes:
Locations:
city: Caen
country: France
facility: Centre François BACLESSE
state: Calvados
Study officials:
affiliation: Centre François Baclesse
name: Marie-Christine GRACH, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01902485: Study of Immediate Start of Progestin Contraceptives in Medical Abortion
Official title: Immediate Initiation of Progestin Contraceptives in First Trimester Medical Abortion: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Contraception
Keywords: Contraception
Medical Abortion
Implant
Injectable
Quickstart
Lead sponsor: Gynuity Health Projects
Sponsor class: OTHER
First posted: 2013-07-18
Enrollment: 937
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study will compare immediate to post-abortion start of two progestin-based contraceptives (DMPA and etonorgestrel implants) among women having first trimester medical abortion who wish to use that method for post-abortion contraception.


Eligibility criteria: Inclusion Criteria:

Women having medical abortion desiring progestin-based contraceptives (injectables or implants)

Primary outcomes:
measure: Medical Abortion Failure
timeFrame: One month after enrollment
measure: Repeat Pregnancy
timeFrame: 6 months after enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Chula Vista
country: United States
facility: Planned Parenthood of the Pacific Southwest
state: California
city: Eureka
country: United States
facility: Planned Parenthood Northern California
state: California
city: Stamford
country: United States
facility: Planned Parenthood of Southern New England
state: Connecticut
city: Baltimore
country: United States
facility: Bayview Medical Center
state: Maryland
city: Boston
country: United States
facility: Boston Medical Center
state: Massachusetts
city: Boston
country: United States
facility: Planned Parenthood League of Massachusetts
state: Massachusetts
city: Mexico City
country: Mexico
facility: Centro de Salud Beatriz Velasco de Aleman
city: Mexico City
country: Mexico
facility: Centro de Salud Santa Catarina
Study officials:
References:
citation: Raymond EG, Weaver MA, Louie KS, Tan YL, Bousieguez M, Arangure-Peraza AG, Lugo-Hernandez EM, Sanhueza P, Goldberg AB, Culwell KR, Kaplan C, Memmel L, Sonalkar S, Jamshidi R, Winikoff B. Effects of Depot Medroxyprogesterone Acetate Injection Timing on Medical Abortion Efficacy and Repeat Pregnancy: A Randomized Controlled Trial. Obstet Gynecol. 2016 Oct;128(4):739-45. doi: 10.1097/AOG.0000000000001627.
citation: Raymond EG, Weaver MA, Tan YL, Louie KS, Bousieguez M, Lugo-Hernandez EM, Arangure-Peraza AG, Sanhueza P, Kaplan C, Sonalkar S, Goldberg AB, Culwell KR, Memmel L, Jamshidi R, Winikoff B. Effect of Immediate Compared With Delayed Insertion of Etonogestrel Implants on Medical Abortion Efficacy and Repeat Pregnancy: A Randomized Controlled Trial. Obstet Gynecol. 2016 Feb;127(2):306-12. doi: 10.1097/AOG.0000000000001274.
Clinical trial NCT05127785: Frailty in Individuals With Advanced Heart Failure Part 2
Official title: Frailty in Individuals With Advanced Heart Failure Part 2
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Heart Failure
Frailty
Lead sponsor: University of Southern California
Sponsor class: OTHER
First posted: 2021-11-19
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals with heart failure undergoing evaluation for advanced heart failure therapy.

Brief summary: To investigate how measures of frailty, assessed during occupational therapy (OT) evaluation and intervention impact decision for advanced heart failure (HF) therapies and postoperative outcomes.


Eligibility criteria: Inclusion Criteria:

* Individuals will be included in this study if they were evaluated for advanced heart failure therapies at Keck Hospital from 1/1/2019-6/30/2021. This will be determined through data from the electronic medical record.

Exclusion Criteria:

* Patients who did not receive an occupational therapy evaluation prior to advanced heart failure intervention decision.

Primary outcomes:
measure: Hospital Length of Stay
timeFrame: 1 to 500 days
measure: Rate of Readmission
timeFrame: 30 to 90 days
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Keck Hospital of USC
state: California
Study officials:
affiliation: University of Southern California
name: Elyse Peterson, OTD, OTR/L
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00254085: Substitution of First Phase Insulin Response in Patient With Type 2 Diabetes.
Official title: Multiple Substitution of First Phase Insulin Response With a Rapid Action Insuli Analogue in Patient With Newly Diagnosed Type 2 Diabtes.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Type 2 Diabetes
Keywords: Type 2 diabtes
Postprandial hyperglycemia
Insulin treatment
Lead sponsor: University Hospital, Gentofte, Copenhagen
Sponsor class: OTHER
First posted: 2005-11-15
Enrollment: 20
Sex: ALL
Minimum age (years): 35
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of the project is to shown whether a little dose of a short acting insulin analogue given 3 time daily before the meals compared with placebo could normalise the increase in blood glucose after teh meals in diet treated Type 2 diabetic patients.

Detailed description: Patients with Type 2 diabtes has a defect in the insulinsecretion combined with an increased insulin resistance. At an intravenously glucosestimulation, patients with Type 2 diabtes has a decresed first phase insulin response compared to healty peoples. Because the hyperglycemia after meal, observed i Type 2 diabetics patients, is related to the defect in the first phase insulin response it is our hypothesis that substitution of the first phase insulin response with a little dose of insulin could normalise the blood glucose after the meal.

20 patients with Type 2 diabetes will in a randomised, placebocontrolled, dobble-dummy study be included for three days treatment with Insulin aspart vs placebo. Primary endpoint is bloodglucose fluctuations monitored by a continously glucose monitor.

Eligibility criteria: Inclusion Criteria:

Type 2 diabtes according to the WHO criteria Fasting blood glucose \>7 HbA1c between 6-9 Normal liver function Normal renal function

-

Exclusion Criteria:

Ongoing treatment with antidiabetic medicine Pregnancy and lactation -

Primary outcomes:
measure: Blood glucose fluctuations
Secondary outcomes:
measure: number of hypoglycemia
Other outcomes:
Locations:
city: Hellerup
country: Denmark
facility: Gentofte University Hospital
Study officials:
affiliation: Gentofte University Hospital
name: Charlotte Gredal, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gredal C, Rosenfalck AM, Dejgaard A, Hilsted J. Targeting postprandial hyperglycaemia in patients with recently diagnosed type 2 diabetes with a fixed, weight-based dose of insulin Aspart. Scand J Clin Lab Invest. 2008;68(8):739-44. doi: 10.1080/00365510802207982.
Clinical trial NCT00507637: Blepharospasm Short Interval
Official title: Prospective, Open-label, Single-arm, Single-center Trial to Investigate the Tolerability of NT 201 and Quality of Life of Patients in the Treatment of Blepharospasm With Shortened Injection Intervals
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Blepharospasm
Lead sponsor: Merz Pharmaceuticals GmbH
Sponsor class: INDUSTRY
First posted: 2007-07-26
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this Phase II study is to show that pre-treated patients with BEB with the need of shortened injection intervals achieve an improved and stable quality of life level if they receive repeated NT 201 injections at short injection intervals. In addition, the tolerability of repeated shortened NT 201 administrations in patients with BEB including the development of neutralizing antibodies will be investigated.


Eligibility criteria: Inclusion Criteria:

* A clinical diagnosis of bilateral BEB characterized by spontaneous, spasmodic, intermittent or persistent involuntary contractions of the orbicular oculi muscles
* Medical need for treatment with shortened injection intervals (\< 12 weeks) confirmed by the patient and investigator
* Blepharospasm Disability Index (BSDI) at baseline visit before injection of \> / = 1,6

Exclusion Criteria:

* Atypical variant of blepharospasm caused by inhibition of levator palpebrae muscle (apraxia of the eyelid)
* Generalized disorders of muscle activity (e.g. myasthenia gravis, Lambert-Eaton syndrome), as well as amyotrophic lateral sclerosis or any other significant neuromuscular disease which might interfere with the trial
* The previous three injections with Botulinum toxin Type A with more than 50 Units \[U\] per eye per injection session
* Treatment with Botulinum toxins for any indication other than BEB within 4 months prior to baseline and during the trial

Primary outcomes:
measure: The difference between the actual Blepharospasm Disability Index [BSDI] value at each follow up visit and the BSDI value at baseline.
timeFrame: From baseline up to week 62. Follow up visits include 8 injection visits (V2 to V8) with intervals of at least 6 weeks between injections.
Secondary outcomes:
measure: Change in Jankovic Rating Scale (JRS) score from baseline over time.
timeFrame: From baseline up to week 62
measure: Patient Evaluation of Global Response [PEGR] rated by patient at visits V2 to V8 and at follow-up visit
timeFrame: Week 6 up to week 62
Other outcomes:
Locations:
city: Bonn
country: Germany
facility: Universitaets Augenklinik
Study officials:
affiliation: Universitaets Augenklinik Bonn
name: Bettina Wabbels, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00108537: Non-Nicotine Agents for Smoking Cessation
Official title: Non-Nicotine Agents for Smoking Cessation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Tobacco Use Disorder
Keywords: smoking
nicotine
drug therapy
smoking cessation
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2005-04-18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to determine which is the better approach to smoking cessation in veterans: bupropion combined with transdermal nicotine or high dose nicotine replacement therapy (NRT) using transdermal nicotine combined with nicotine inhaler.

Detailed description: This study is a two-arm open-label, randomized controlled trial of bupropion combined with transdermal nicotine versus high dose NRT (transdermal nicotine and nicotine inhaler) with all subjects receiving a behavioral counseling program for smoking cessation.

Eligibility criteria: Inclusion Criteria:

* Readiness to set a quit date in the next two weeks,
* Current smoking of at least 15 cigarettes a day

Exclusion Criteria:

* Current untreated depression or receiving treatment for depression,
* History of seizures, major head injury, or other predisposition for seizures

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: Denver VA Medical Center
state: Colorado
Study officials:
References: